FRANKFURT (Reuters) - Biotest BIOG_p.DE Chief Executive Bernhard Ehmer told a press conference on Thursday that China's Creat Group has not been the only suitor approaching Biotest about a deal but it chose to talk to Creat because the proposal was "thought through".
Creat is seeking to buy the German blood plasma products maker for about 1.2 billion euros ($1.3 billion) including debt following its purchase last year of British peer Bio Products Laboratory.
Reporting by Patricia Weiss; Writing by Ludwig Burger
Our Standards: The Thomson Reuters Trust Principles.